Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis - Trial NCT06290934
Access comprehensive clinical trial information for NCT06290934 through Pure Global AI's free database. This Phase 2 trial is sponsored by Gilead Sciences and is currently Not yet recruiting. The study focuses on Ulcerative Colitis. Target enrollment is 423 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Gilead Sciences
Timeline & Enrollment
Phase 2
Mar 01, 2024
Mar 01, 2028
Primary Outcome
Parts 1 and 2: Proportion of Participants Achieving Clinical Response at Week 12
Summary
The goal of this study is to learn if GS-1427 is effective and safe in treating participants
 with moderate to severe ulcerative colitis. The study will compare participants in different
 treatment groups treated with GS-1427 with participants treated with placebo (Part 1), and
 participants treated with GS-1427 or ustekinumab alone with participants treated with GS-1427
 in combination with ustekinumab (Part 2).
 
 The primary objectives of this study are:
 
 Part 1: To assess the efficacy of GS-1427, compared with placebo control, in achieving
 clinical response at Week 12
 
 Part 2: To assess the efficacy of combination therapy with GS-1427 and ustekinumab, compared
 with GS-1427 and ustekinumab monotherapies, in achieving clinical response at Week 12
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06290934
Non-Device Trial